What is ReliantHeart?
ReliantHeart Inc. stands at the forefront of innovation in mechanical circulatory support, developing cutting-edge therapies for patients suffering from advanced stage heart failure. The company's flagship product, the HeartAssist5®, is a next-generation ventricular assist device (VAD) that has received CE Mark approval for commercial sale in Europe. This implantable, electric pump is engineered for individuals with end-stage heart failure and distinguishes itself as the world's only remotely monitored VAD, offering enhanced patient care and operational efficiency.
How much funding has ReliantHeart raised?
ReliantHeart has raised a total of $5.5M across 3 funding rounds:
Private Equity
$3.9M
Debt
$1.5M
Debt
$150K
Private Equity (2015): $3.9M, investors not publicly disclosed
Debt (2017): $1.5M, investors not publicly disclosed
Debt (2020): $150K supported by PPP
What's next for ReliantHeart?
With the recent major strategic investment, ReliantHeart is poised for significant expansion. The company's focus on advanced VAD technology, particularly the remotely monitored HeartAssist5®, positions it to capture a larger share of the growing market for mechanical circulatory support. Future endeavors will likely involve scaling manufacturing, expanding clinical trials, and broadening its commercial reach, particularly in markets where advanced heart failure treatment is a priority. The substantial backing suggests a strategic push towards market leadership and further product development.
See full ReliantHeart company page
